Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Memorial Sloan Kettering Cancer Center · Cornell University · +18 more institutions
Abstract
, locking it in its inactive state. Adagrasib showed clinical activity and had an acceptable adverse-event profile in the phase 1-1b part of the KRYSTAL-1 phase 1-2 study.
-mutated non-small-cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy and anti-programmed death 1 or programmed death ligand 1 therapy. The primary end point was objective response assessed by blinded independent central review. Secondary end points included the duration of response, progression-free survival, overall survival, and safety.
Citation impact
- FWCI
- 128.58
- Percentile
- 100%
- References
- 27
Authors
22- PAPasi A. JänneCorresponding
Memorial Sloan Kettering Cancer Center, Cornell University, Dana-Farber Cancer Institute
- GJGregory J. Riely
Memorial Sloan Kettering Cancer Center, Cornell University
- SMShirish M. Gadgeel
Memorial Sloan Kettering Cancer Center, Cornell University, Henry Ford Hospital
- RSRebecca S. Heist
Memorial Sloan Kettering Cancer Center, Cornell University, Massachusetts General Hospital
- SISai‐Hong Ignatius Ou
Memorial Sloan Kettering Cancer Center, University of California, Irvine, Cornell University
Topics & keywords
- KRAS
- Mutation
- Cancer research
- Cancer
- Lung cancer
- Medicine
- Genetics
- Biology
- Good health and well-being